Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring <i>MET</i> Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models.

Engstrom, Lars D; Aranda, Ruth; Lee, Matthew; Tovar, Elizabeth A; Essenburg, Curt J; Madaj, Zachary; Chiang, Harrah; Briere, David; Hallin, Jill; Lopez-Casas, Pedro P; Baños, Natalia; Menendez, Camino; Hidalgo, Manuel; Tassell, Vanessa; Chao, Richard; Chudova, Darya I; Lanman, Richard B; Olson, Peter; Bazhenova, Lyudmilla; Patel, Sandip Pravin; Graveel, Carrie; Nishino, Mizuki; Shapiro, Geoffrey I; Peled, Nir; Awad, Mark M; Jänne, Pasi A; Christensen, James G

Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models.

Engstrom, Lars D; Aranda, Ruth; Lee, Matthew; Tovar, Elizabeth A; Essenburg, Curt J; Madaj, Zachary; Chiang, Harrah; Briere, David; Hallin, Jill; Lopez-Casas, Pedro P; Baños, Natalia; Menendez, Camino; Hidalgo, Manuel; Tassell, Vanessa; Chao, Richard; Chudova, Darya I; Lanman, Richard B; Olson, Peter; Bazhenova, Lyudmilla; Patel, Sandip Pravin; Graveel, Carrie; Nishino, Mizuki; Shapiro, Geoffrey I; Peled, Nir; Awad, Mark M; Jänne, Pasi A; Christensen, James G.

Afiliación

Engstrom LD; Mirati Therapeutics, Inc., San Diego, California.
Aranda R; Mirati Therapeutics, Inc., San Diego, California.
Lee M; Mirati Therapeutics, Inc., San Diego, California.
Tovar EA; Van Andel Research Institute, Grand Rapids, Michigan.
Essenburg CJ; Van Andel Research Institute, Grand Rapids, Michigan.
Madaj Z; Van Andel Research Institute, Grand Rapids, Michigan.
Chiang H; Mirati Therapeutics, Inc., San Diego, California.
Briere D; Mirati Therapeutics, Inc., San Diego, California.
Hallin J; Mirati Therapeutics, Inc., San Diego, California.
Lopez-Casas PP; Centro Nacional de Investigaciones Oncológicas (Spanish National Cancer Research Centre), Madrid, Spain.
Baños N; Centro Nacional de Investigaciones Oncológicas (Spanish National Cancer Research Centre), Madrid, Spain.
Menendez C; Centro Nacional de Investigaciones Oncológicas (Spanish National Cancer Research Centre), Madrid, Spain.
Hidalgo M; Centro Nacional de Investigaciones Oncológicas (Spanish National Cancer Research Centre), Madrid, Spain.
Tassell V; Mirati Therapeutics, Inc., San Diego, California.
Chao R; Mirati Therapeutics, Inc., San Diego, California.
Chudova DI; Guardant Health, Inc., Redwood City, California.
Lanman RB; Guardant Health, Inc., Redwood City, California.
Olson P; Mirati Therapeutics, Inc., San Diego, California.
Bazhenova L; Moores Cancer Center, University of California, San Diego, San Diego, California.
Patel SP; Moores Cancer Center, University of California, San Diego, San Diego, California.
Graveel C; Van Andel Research Institute, Grand Rapids, Michigan.
Nishino M; Department of Radiology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts.
Shapiro GI; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Peled N; Sheba Medical Center, Tel-Aviv University, Ramat-Gan, Israel.
Awad MM; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Jänne PA; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Christensen JG; Mirati Therapeutics, Inc., San Diego, California. christensenj@mirati.com.

Clin Cancer Res ; 23(21): 6661-6672, 2017 Nov 01.

Article en En | MEDLINE | ID: mdl-28765324

Asunto(s)

Antineoplásicos/uso terapéutico; Bencenoacetamidas/uso terapéutico; Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico; Resistencia a Antineoplásicos/efectos de los fármacos; Neoplasias Hepáticas/tratamiento farmacológico; Proteínas Proto-Oncogénicas c-met/antagonistas & inhibidores; Piridinas/uso terapéutico; Adulto; Anciano; Animales; Antineoplásicos/farmacología; Bencenoacetamidas/farmacología; Carcinoma de Pulmón de Células no Pequeñas/genética; Carcinoma de Pulmón de Células no Pequeñas/patología; Línea Celular Tumoral; Crizotinib; Exones/genética; Femenino; Humanos; Neoplasias Hepáticas/genética; Neoplasias Hepáticas/patología; Neoplasias Hepáticas/secundario; Masculino; Ratones; Persona de Mediana Edad; Mutación; Inhibidores de Proteínas Quinasas/administración & dosificación; Inhibidores de Proteínas Quinasas/efectos adversos; Proteínas Proto-Oncogénicas c-met/genética; Pirazoles/administración & dosificación; Piridinas/administración & dosificación; Piridinas/farmacología; Ensayos Antitumor por Modelo de Xenoinjerto

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Piridinas / Carcinoma de Pulmón de Células no Pequeñas / Resistencia a Antineoplásicos / Proteínas Proto-Oncogénicas c-met / Bencenoacetamidas / Neoplasias Hepáticas / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Animals / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2017 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google